Background/Aims: Hyperlipidemia induces dysfunction in the smooth muscle cells (SMCs) of the blood vessels, and the vascular remodeling that ensues is a key proatherogenic factor contributing to cardiovascular events. Chemokines and chemokine receptors play crucial roles in vascular remodeling. Here, we examined whether the hyperlipidemia-derived chemokine CCL5 and its receptor CCR5 influence vascular SMC proliferation, phenotypic switching, and explored the underlying mechanisms. Methods: Thoracoabdominal aorta were isolated from wild-type, CCL5 and CCR5 double-knockout mice (CCL5 −/− CCR5 −/− ) fed a high-fat diet (HFD) for 12 weeks. Expression of the contractile, synthetic, and proliferation markers were assayed using immunohistochemical and western blotting. The effects of CCL5 and palmitic acid on cultured SMC proliferation and phenotypic modulation were evaluated using flow cytometry, bromodeoxyuridine (BrdU), and western blotting. Results: Wild-type mice fed an HFD showed markedly increased total cholesterol, triglyceride, and CCL5 serum levels, as well as significantly increased CCL5 and CCR5 expression in the thoracoabdominal aorta vs. normaldiet-fed controls. HFD-fed CCL5 −/− CCR5 −/− mice showed significantly decreased expression of the synthetic phenotype marker osteopontin and the proliferation marker proliferating cell nuclear antigen, and increased expression of the contractile phenotype marker smooth 
Introduction
Abnormal phenotypic modulation in vascular smooth muscle cells (SMCs) is a critical factor affecting vascular function and contributes to diseases such as atherosclerosis [1] . In normal and mature vessels, SMCs exhibit a spindle-like, elongated morphology with normal cell size, proliferation and migration rates, and extracellular matrix (ECM) production. These phenotypes are associated with increases in the expression levels of contractile or differentiated phenotype marker proteins, such as smooth muscle myosin heavy chain (SM-MHC), h-caldesmon, and smooth muscle a-actin (SMa-actin) [2, 3] . During vascular remodeling resulting from the development of pathogenic lesions, SMCs undergo "phenotypic switching" or "activation" which results in phenotypic alteration from physiological contractile to pathophysiological synthetic phenotype. These cells exhibit abnormal proliferation and migration rates; increased expression of synthetic or dedifferentiated phenotype marker proteins including vimentin and osteopontin also occurs [4, 5] . This switch from a contractile to synthetic phenotype has been established as an important process in atherogenesis. There is increasing evidence that chronic inflammation in the blood vessels caused by hyperlipidemia is a critical risk factor in the development and aggravation of atherosclerosis and cardiovascular disease. However, the mechanisms by which high lipid levels drive the phenotypic modulation of SMCs remain unclear.
High circulating lipid levels lead to chronic inflammation, which attracts chemokines into the artery wall [6] . These inflammatory molecules further induce vascular dysfunction. SMC dysfunction is associated with loss of normal characteristics, which induces vascular remodeling. Various cellular processes have been proposed in the remodeling of smooth muscle including proliferation, migration, and ECM production and degradation [7, 8] .
Hyperlipidemia has been reported to induce SMC proliferation, resulting in vascular remodeling [9, 10] . A recent study demonstrated that a high-fat diet (HFD) induced hyperlipidemia in rats, promoting the switch to a synthetic phenotype in vascular SMCs [11] . However, the precise mechanisms by which dyslipidemia alters the function of SMCs under pathological conditions, such as proliferation and phenotypic changes, have not been fully elucidated.
Chemokines are chemotactic cytokines (chemo-attractive cytokines) that play important roles in cardiovascular disease by recruiting inflammatory immune cells to the blood vessels [12] . The functions of chemokines involve triggering recruitment of immune cell and migration through activation of seven-transmembrane G-protein-coupled receptors located on the surface of target cells [13] . Chemokine (C-C motif) ligand 5 (CCL5), also known as regulated on activation normal T cell expressed and secreted (RANTES), is one of the most important chemokines secreted from activated platelets, T cells, and macrophages, as well as endothelial cells (ECs) and SMCs [14] . CCL5 has multiple potential receptors including CC-chemokine receptor 1 (CCR1), CCR3, and CCR5. CCR5 is an important receptor for CCL5 that is also expressed on macrophages, T cells, ECs, and SMCs [15, 16] . Previous studies have demonstrated that hyperlipidemia increases the level of serum CCL5, indicating that dyslipidemia influences chemokine expression [17, 18] . Elevated serum CCL5 has also been reported in patients in the early stages of atherosclerosis [19] . Studies involving in vivo and in vitro models have shown that CCL5 or CCR5 deficiency significantly reduced atherosclerosis and neointima formation [20] [21] [22] [23] . CCR5 facilitates atherosclerotic plaque stabilization, and its blockade could reduce plaque formation [24, 25] . Collectively, these previous reports indicate that CCL5 and CCR5 may serve as a key chemokine and chemokine receptor, respectively, in atherogenesis development and progression. However, whether the proatherogenic factor hyperlipidemia itself triggers CCL5 and CCR5 expression and activation in the blood vessels, and the effects of CCL5 and CCR5 on the pathological behaviors of SMCs, such as proliferation and phenotypic switching, have not been addressed. Therefore, in the present study, we investigated the proatherogenic role of the CCL5/CCR5 axis in vivo and the associated cellular mechanisms. Our findings further elucidate the mechanisms by which the CCL5/CCR5 axis exerts proatherosclerotic effects through modulation of abnormal proliferation and pathological phenotype formation of SMCs.
Materials and Methods

Cell culture and drug treatment
Human aortic SMCs (HASMCs) were obtained from Lonza, Inc., (Allendale, NJ) and Cell Applications Inc., (San Diego, CA). The cells were cultured in Ham's F-12K medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells at passage 5 or 6 were used. After cells were grown to 70%-80% confluence, they were serum-starved in F-12K medium with 1% FBS for 24 h. After starvation, the HASMCs were pretreated with or without maraviroc (MVC; 10 mmol/L) or Bay11-7085 (5 mmol/L) (both from Sigma-Aldrich, St. Louis, MO) for 1 h, and then stimulated with CCL5 (R&D Systems, Inc., Minneapolis, MN) in the presence of the reagent.
Animals
The animals used in this study included male CCL5 −/− CCR5 −/− double-knockout mice and age-matched male C57BL/6J mice to serve as the wild-type (WT) control on a pure C57BL/6J background. CCL5 −/− CCR5 −/− double-knockout mice were kindly provided by Dr. Yuan-Ji Day (Hualien Tzu Chi Hospital, Hualien, Taiwan). Eight-week-old male C57BL/6J and double-knockout mice were fed an HFD (60% fat; Research Diets, Inc., New Brunswick, NJ) for 12 weeks to induce hyperlipidemia [26] . At 20 weeks, mice were euthanized by administering intraperitoneal injection of pentobarbital sodium (150 mg/kg) and then the thoracoabdominal aorta was harvested for protein and immunohistochemical analysis. All animal experimental procedures were in accordance with the stipulations of the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 2011) with approval from the ethical review board of the National Defense Medical Center, which is certified by the Association of Assessment and Accreditation of Laboratory Animal Care.
Serum lipid and CCL5 levels
Serum total cholesterol, triglyceride levels were assayed using commercially available kits (Randox Laboratories, Ltd., Crumlin, N. Ireland); serum CCL5 levels were quantified using the corresponding enzyme-linked immunosorbent assay (ELISA) detection kit (R&D Systems) according to the manufacturer's instructions. 
Bromodeoxyuridine (BrdU) incorporation assay
Flow cytometry analysis
Cell cycle distribution was analyzed by using flow cytometry. In brief, the cells were harvested using trypsin-ethylenediaminetetraacetic acid, washed once with ice-cold phosphate-buffered saline (PBS), and then fixed in cold 70% ethanol. Next, they were permeabilized by incubation with 0.2% Tween 20 and 1 mg/mL RNase A in PBS for 30 min. Cells were then washed in PBS and stained with 50 mg/mL propidium iodide (Roche, Basel, Switzerland). Stained cells were analyzed using a FACScan flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ), and the cell cycle distribution was analyzed using ModFit cell cycle analysis software.
Cell viability assay
Cell viability was evaluated with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. HASMCs were seeded in 96-well plates at 2 × 10 4 cells/well in culture medium and treated with 0.1, 1, 5, and 10 mmol//L of MVC for 24 h. Purple formazan, the insoluble metabolite formed by metabolism of MTT by mitochondrial dehydrogenases, was quantified on an ELISA reader at 550 nm.
Western blotting
Western blotting was performed for HASMC lysates using a previously described standard protocol [27] . HASMCs were collected by scraping and lysed with RIPA buffer containing a protease and phosphatase inhibitor mixture (Roche). The total cell lysate, containing equal amounts of protein across samples, was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes were then incubated with the following antibodies: rabbit polyclonal antibodies against CDK2, CDK4, cyclin D1, cyclin E, p27 kip1 , Akt, phospho-Akt (Ser473), p38, phospho-p38, p70 ribosomal S6 kinase (p70S6K), phospho-p70S6K, IκBa, phospho-IκBa, phospho-retinoblastoma protein (pRB), vimentin, nuclear factor-kappa B (NF-κB) p65, and lamin B1; mouse monoclonal antibodies against extracellular signal-regulated kinase (ERK)1/2 and phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA); and mouse monoclonal antibodies against h-caldesmon, SM-MHC, SMα-actin, and α-tubulin (Sigma-Aldrich). The Western-Light chemiluminescent detection system (Applied Biosystems, Foster City, CA) was used for immunodetection.
Preparation of cytoplasmic fractions and nuclear extracts
For the NF-κB p65 translocation experiment, nuclear and cytoplasmic proteins were extracted from HASMCs by using NE-PER Nuclear and Cytoplasmic Extraction kits (Thermo Fisher Scientific). Cells were treated with CCL5 (5 nmol/L) for 15, 30, and 60 min, and then both nuclear and cytosolic fractions were analyzed by using western blotting with anti-p65 antibody.
Small interfering RNA (siRNA) transfection CCR5-specific and control siRNAs were purchased from Dharmacon Inc., (Chicago, IL). The day before transfection, cells were cultured in 6-cm dishes to 70%-80% confluence. After 16 h, the cells were transfected with the designated siRNA at concentrations of 20, 50, and 100 nmol/L using RNAiMAX reagent (Invitrogen, Carlsbad, CA).
Immunohistochemistry
Thoracoabdominal aorta isolated from the mice were fixed with 4% paraformaldehyde and flash-frozen in optical coherence tomography embedding compound (Labtek Inc., Grand Rapids, MI). Immunohistochemical staining was performed as previously described [27] . Artery sections were reacted with anti-CCL5, anti-CCR5 (R&D Systems), anti-SMa-actin (Sigma-Aldrich), anti-osteopontin (Abcam, Cambridge, MA, USA), and anti-proliferating cell nuclear antigen (anti-PCNA) (Santa Cruz Biotechnology, Dallas, TX). The color reaction was obtained by using diaminobenzidine tetrahydrochloride followed by counterstaining with hematoxylin for morphological assessment; 6-9 animals were examined in each group. 
Statistical analysis
Results are expressed as the mean ± standard error of the mean (SEM) from at least three independent experiments. Statistical analysis was performed using Student's t test for two groups of data; one-way analysis of variance followed by Scheffe's test was used for multiple comparisons. P < 0.05 was deemed statistical significance.
Results
Body weight and serum lipid levels
Serum lipid profiles were examined to confirm the effect of HFD in the mice. As expected, after 12 weeks of consumption of HFD, body weight and serum total cholesterol, and triglyceride levels were significantly higher than those in mice fed a normal diet ( Table  1 ). The HFD-induced increase in serum total cholesterol and triglyceride were not affected by CCL5 −/− CCR5 −/− double-knockout. These findings demonstrate that the HFD-fed mice are a valid model of hyperlipidemia.
HFD/ free fatty acids (FFA)-induced CCL5/CCR5 expression influences vascular remodeling
We investigated the effects of HFD on CCL5 and CCR5 expression levels in the aorta of mice. Immunohistochemical staining and western blot analysis clearly showed that CCL5 and CCR5 basal expression was negligible in normal vessels (Fig. 1A-C) . In contrast, after HFD consumption for 12 weeks, the aorta exhibited significantly higher CCL5 and CCR5 expression (Fig. 1A-C) . Immunohistochemistry results showed that the aorta from HFD-fed mice had significantly decreased expression of the contractile marker SMa-actin, whereas expression of the synthetic marker osteopontin was significantly increased compared with that in the normal diet-fed mice. Moreover, expression of the proliferative index marker PCNA was significantly higher in the HFD-fed mice (Fig. 1D-F) . In contrast, HFD-fed doubleknockout (CCL5 −/− CCR5 −/− ) mice had significantly increased expression of the contractile phenotype marker SMa-actin and reduced osteopontin and PCNA expression compared with HFD-fed WT mice (Fig. 1D-F) . Western blot analysis confirmed the immunostaining results for the effect of the CCL5/CCR5 axis on the phenotypic modulation of HFD-fed animals ( Fig.  1G and H) . In addition, the serum concentrations of CCL5 in the mice from each group were measured. Serum CCL5 levels were significantly elevated in HFD-fed mice compared with normal diet-fed mice. (Fig. 1I) . These results indicate that the systemic inflammatory status was increased in mice under HFD feeding. We examined whether hyperlipidemia associated with increased FFA levels is tightly linked with CCL5, CCR5, and vascular remodeling. Incubation of primary HASMCs with palmitic acid (PA) showed significantly increased expression of CCL5, CCR5, synthetic marker osteopontin, and proliferation marker PCNA. Expression of contractile marker SMa-actin was significantly decreased in the PA-treated group (Fig. 1J ). These results demonstrate that CCL5 and CCR5 may play a significant role in the conversion of SMCs from a physiological contractile to a pathological synthetic phenotype, thereby participating in the vascular remodeling in hyperlipidemia.
CCL5 induces aortic SMC proliferation
Since the HFD-fed mice serum contained significantly higher levels of CCL5 compared with normal diet-fed mice, hyperlipidemia-induced serum CCL5 levels Table 1 . Body weight and serum lipid levels of three groups of mice at week 20 (at the end of the experiment). ND: normal diet; HFD: high-fat diet. Data are presented as the means ± SEM (n = 6-9). *P < 0.05 versus the ND group. #P < 0.05 versus the wild-type HFD group Fig. 2A) . Western blot analysis showed that levels of the cell cycle regulatory proteins CDK2, CDK4, cyclin D1, cyclin E, and pRB significantly increased, whereas the level of p27 kip1 , a cyclin-dependent kinase inhibitor, decreased compared with those of untreated control cells (Fig. 2B) . These CCL5-induced effects in SMCs were sustained for up to 48 h (Fig. 2C) . To assess the role of CCR5 (the major receptor of CCL5 alone) in CCL5-induced SMC proliferation, the cells were treated with various concentrations of the CCR5 antagonist MVC. CCL5-induced SMC proliferation was significantly reduced and returned to the basal level with 10 mmol/L MVC treatment, compared with cells treated with CCL5 alone (Fig. 2D) . Flow cytometry confirmed this CCL5-induced proliferation with dominance of the S phase transition, which was reversed by incubation of SMCs with MVC prior to CCL5 stimulation ( Fig. 2E and F) . As shown in Fig. 2G , the MTT assay indicated no effect on cell viability when the SMCs were treated with up to 10 mmol/L MVC for 24 h, thereby ruling out the possibility that the observed inhibition of SMC proliferation by MVC is related to 
a direct cytotoxic effect. These findings provide evidence that CCL5 directly induced SMC proliferation without causing cell death, and that these effects are mediated through CCR5.
CCL5 modulates aortic SMCs from a contractile to a synthetic phenotype
To investigate whether CCL5 induces SMC phenotypic switching, we examined the effects of CCL5 (at two time points, 24 and 48 h, and over a concentration range of 0.1-100 nmol/L) on contractile and synthetic phenotype biomarker expression. As shown in Fig. 3A for SMCs incubated with different concentrations of CCL5 for 24 h, expression levels of the contractile markers SM-MHC and h-caldesmon significantly decreased in a concentration-dependent manner. For SM-MHC, the decrease began with CCL5 at 1 nmol/L and became more extensive at 5 nmol/L, but was then diminished at 10 nmol/L and became insignificant at 100 nmol/L, showing a biphasic response. For h-caldesmon, the decrease also began at 1 nmol/L, but remained constant over 1-100 nmol/L. In contrast, the synthetic phenotype marker vimentin showed a significant increase beginning at 1 nmol/L, reaching a plateau at 5-100 nmol/L. Fig. 3B shows the results for SMCs incubated with different CCL5 concentrations for 48 h; SM-MHC exhibited a biphasic trend similar to that observed at 24 h. The h-caldesmon level decreased in response to 5 and 10 nmol/L CCL5, but showed no change at 100 nmol/L. The synthetic phenotype marker vimentin exhibited the same pattern as in the 24-h study. These results demonstrate that CCL5 modulates SMC phenotypic switching from a contractile to a synthetic phenotype.
CCL5 activates ERK1/2, Akt/p70S6K, p38, and IκBα in SMCs
Mitogen-activated protein kinase (MAPK) and activation of Akt signaling play major roles in the modulation of cellular functions including proliferation, differentiation, and [28] . Expression of cytokines and chemokines during inflammation is regulated by the MAPK and NF-κB signaling pathways [29] . Therefore, to determine whether the effect of CCL5 on the phenotypic switching in SMCs may be at least partly mediated through these signaling pathways, we investigated the effects of CCL5 on ERK, Akt/p70S6K, p38, and NF-κB in SMCs. As shown in Fig. 4A , stimulation of SMCs with CCL5 for 5 min caused increased ERK1/2 phosphorylation, which peaked at 15 min and then returned to baseline. CCL5 also induced phosphorylation of Akt, p70S6K, and p38, with peaks observed within 30 min in all cases (Fig. 4B-D) . Next, we investigated whether NF-κB was activated in SMCs incubated with CCL5. CCL5 induced significant and time-dependent IκBa degradation in SMCs, accompanied by a significant increase in levels of phosphorylated IκBa (Fig. 4E) . Thus, CCL5 induced NF-κB activation through IκBa phosphorylation and degradation. These results demonstrate the rapid activation of the ERK1/2, Akt/p70S6K, p38, and NF-κB pathways in response to CCL5 in SMCs. Furthermore, these results indicate that CCL5-induced SMC proliferation and phenotypic switching may be related to NF-κB activation.
CCL5 induces the proliferation and synthetic phenotype of SMCs via CCR5 activation
After observing that CCL5 increases SMC proliferation and decreases contractile marker expression, we next tested whether these effects are mediated through a CCR5-dependent pathway. We first examined the effects of CCL5 on CCR5 expression in SMCs at different time points. SMCs incubated with 5 nmol/L CCL5 showed significantly increased CCR5 protein expression levels at 1 h, which were sustained for at least 24 h (Fig. 5A) . To elucidate the role of CCR5 in SMC proliferation, the cells were incubated with the CCR5 antagonist MVC for 1 
h before and during CCL5 treatment, which resulted in reduced CCL5-induced expression of the cell cycle regulatory proteins CDK2, CDK4, cyclin D1, cyclin E, and pRB, and an increase in the expression of p27 kip1 , a cyclin-dependent kinase inhibitor (Fig. 5B) . To elucidate the role of CCR5 in phenotypic switching in SMCs stimulated with CCL5, we next examined whether cells with inhibition of CCR5 tended toward the contractile phenotype. As shown in Fig. 5C , MVC significantly inhibited the CCL5-induced protein expression of vimentin and increased h-caldesmon and SM-MHC expression in SMCs. The involvement of CCR5 in CCL5-induced SMC proliferation and phenotypic switching was further confirmed by transfecting cells with the CCR5-specific siRNA, which inhibited CCR5 protein expression by almost 90% at 50 nmol/L compared with cells transfected with control siRNA (Fig. 5D) . Similarly, CCR5 knockdown resulted in a significant decrease in the CCL5-induced protein expression of CDK2, CDK4, cyclin D1, cyclin E, pRB, and PCNA, while increasing the p27 kip1 level (Fig. 5E) . In contrast, the CCL5-induced decreases in SM-MHC and h-caldesmon levels and increase in vimentin levels were further reversed in SMCs upon silencing of the CCR5 gene (Fig. 5F ). These results demonstrate that CCR5 is clearly involved in CCL5-induced contractile-to-synthetic phenotype switching and the enhanced proliferation of SMCs.
CCL5 induces SMC proliferation and synthetic phenotype through an NF-κB-dependent pathway
The nuclear transcription factor NF-κB has been shown to regulate various genes involved in inflammatory response, differentiation, and proliferation [30] . To determine the effect of CCL5 on NF-κB activation, we investigated its role in NF-κB nuclear translocation. CCL5 treatment induced translocation of NF-κB p65 into the nucleus, accompanied by decreased NF-κB p65 expression in the cytosolic fraction ( Fig. 6A and B) . To determine whether NF-κB contributes to CCL5-induced proliferation and synthetic phenotype formation in SMCs, we used Bay11-7085, an inhibitor of NF-κB, to suppress the activation of NF-κB; Bay11-7085 reversed the CCL5-induced proliferation and synthetic phenotype formation (Fig. 6C and D). Moreover, CCL5 significantly induced CCR5 expression in SMCs after 24 h of stimulation, and this increase in protein expression was significantly inhibited by pretreating the cells with Bay11-7085 ( Fig. 6C and D) . These results indicate a role of NF-κB in mediating CCL5-induced CCR5 expression and suggest that CCL5 stimulates NF-κB-dependent inflammatory signals to induce SMC proliferation, phenotypic switching, and CCR5 expression, and that inhibition of NF-κB signaling can significantly reverse these effects.
Discussion
In this study, we have provided clear evidence that hyperlipidemia induces SMC proliferation and switching to an atherogenic synthetic phenotype by increasing CCL5 production and CCR5 expression. Overall, our results indicate that CCL5 and CCR5 are critical pathogenic factors in vascular remodeling in response to HFD-induced hyperlipidemia.
The most critical factor and initiation step in the development and progression of atherogenesis is elevated circulating levels of lipids, which evokes chronic inflammation and in turn attracts chemokines into the artery wall [31] . Hyperlipidemia is defined as high levels of many different lipids, including FFAs. The new finding in the present study was that the saturated-PA-induced expression of CCL5 and CCR5 was accompanied by a parallel increase in proliferation and this promoted SMC phenotypic changes in from a physiological contractile state to a pathological synthetic state. Our other in vitro findings on the CCL5-mediated induction of SMC synthetic phenotype formation through CCR5 activation suggest that blocking CCR5 may alter the SMC phenotype to a physiological contractile state, while inhibiting SMC proliferation. This notion agrees with the recent report by Podolecet al [19] . showing that the serum CCL5 level was significantly higher in patients at early stages of atherosclerosis. Collectively, these results suggest that inhibition of the CCL5/CCR5 axis would suppress high lipid-induced preatherosclerotic SMC remodeling.
Our in vivo results show that CCL5 and CCR5 expression levels in the aorta or serum levels of CCL5 were markedly higher in HFD-fed mice than in mice fed a normal diet. We postulate that this phenomenon may involve the activation of immune cells (in addition to ECs and SMCs), as these cells secreted CCL5 while exhibiting upregulation of the receptor CCR5 in HFD-induced hyperlipidemia. These results further indicate that many types of cells may contribute to the changes in SMC behavior under hyperlipidemia, especially as circulating immune cells are all in close proximity to the vessel walls, and cell-cell interactions between immune cells and vascular cells occur in both autocrine and paracrine manners. Moreover, mice with genetic deficiencies of the CCL5/CCR5 axis showed significant reductions in SMC proliferation and in the hyperlipidemia-induced transformation of the contractile to the synthetic phenotype. These results clearly indicate that the hyperlipidemia-induced upregulation of both CCL5 and CCR5 may accelerate the progression of vascular remodeling. Therefore, CCL5 and CCR5 may represent an important chemokine and chemokine receptor in hyperlipidemia. Although other factors, such as oxidative stress [32, 33] , have been reported to play a significant role in regulating the behavior of SMCs under hyperlipidemia, our current results provide evidence that CCL5 and its receptor CCR5 may play a crucial role in the hyperlipidemia-induced dysfunction of SMCs.
Interestingly, in the present study, the serum concentration of CCL5 in HFD-fed mice was approximately 50 ng/mL and was able to induce proliferation and synthetic phenotype formation in vivo. However, CCL5 at 5 nmol/L can induce proliferation and synthetic marker expression in cultured SMCs. The minimum dose at which these effects of CCL5 could be observed was 1 nmol/L. Thus, our results suggest that the effective concentration of CCL5 and local CCL5 expression are critical for its paracrine mechanism in SMCs to modulate their phenotype and affect proliferation.
CCL5 can bind three types of receptors: CCR1, CCR3, and CCR5 [14] . CCL5 in complex with CCR5 has been suggested to be crucial in the development of atherogenesis [34] . To date, few studies have explored the atherogenic effects of CCL5 when bound to CCR1 [21, 22] . Conversely, disruption of CCR1 expression may enhance atherogenesis and inflammation development [35] . These findings indicate that CCR1 may exert an atheroprotective effect. As CCR3 expression is negligible in normal blood vessels [36, 37] , its role in atherogenesis remains unclear [12] . Our in vitro and in vivo results suggest that deficiency of CCR5 or both CCL5 and CCR5 has a non-redundant protective effect against pathogenic vascular remodeling. Collectively, the results from cellular experiments and animal models indicate that CCR5 plays a more critical role in the development of atherogenesis than the other two CCL5 receptors.
Emerging evidence suggests that members of the MAPK superfamily regulate cell functions under abnormal conditions, including excessive proliferation and dysregulation of differentiation under inflammation in different cell types [38, 39] . However, the roles of these signaling pathways in the regulation of SMC behavior by CCL5 have not been clarified. A new finding of the present study is that SMCs stimulated with CCL5 rapidly caused increased phosphorylation of ERK, PI3K/Akt, and p38 MAPK within 5 min. The CCL5-induced phosphorylation of PI3K/Akt subsequently activated the downstream target p70S6K. The phosphorylation of all these kinases was maintained for at least 30 min, except for ERK. CCL5 stimulation induced the expression of CCR5, which was sustained for 24 h. In addition, CCL5 induced the translocation of NF-κB p65 from the cytosol to the nucleus, resulting in NF-κB activation. The CCL5-induced CCR5 expression in SMCs was suppressed by treatment with the NF-κB inhibitor Bay11-7085, suggesting that NF-κB activation is indispensable for CCL5-induced CCR5 expression. Moreover, Bay11-7085 inhibited IκBa phosphorylation by reversing CCL5-evoked proliferation and pathological synthetic phenotype formation in SMCs. This finding is consistent with a previous report showing that NF-κB inhibition attenuates SMC phenotypic switching [40] . Thus, our results indicate that CCL5 binds to CCR5 and then turns on a variety of MAPK signaling pathways, which in turn activate NF-κB, resulting in SMC proliferation and phenotype modulation (Fig. 7) .
In conclusion, our present results shed light on the molecular mechanism of hyperlipidemia, which has proatherogenic actions by inducing the expression of CCL5 and its receptor CCR5 to consequentially promote the proliferation of SMCs, as well as their conversion to the atherogenic synthetic phenotype. These results demonstrate that blockade of the CCL5/CCR5 axis could prevent hyperlipidemia-induced inflammatory preatherosclerotic remodeling by modulating SMC phenotypic switching and proliferation. Therefore, inhibition of CCR5 may be a promising target for the prevention or treatment of atherosclerotic diseases induced by hyperlipidemia. 
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